Equitec Proprietary Markets’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Equitec Proprietary Markets’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-45,000	Closed	-$1.62K	–	135
2023 Q1	$1.62K	Hold	45,000	–	–	﹤0.01%	120
2022 Q4	$2.12K	Hold	45,000	–	–	﹤0.01%	160
2022 Q3	$3K	Hold	45,000	–	–	﹤0.01%	208
2022 Q2	$7K	Hold	45,000	–	–	﹤0.01%	194
2022 Q1	$22K	Hold	45,000	–	–	﹤0.01%	142
2021 Q4	$81K	Hold	45,000	–	–	0.01%	178
2021 Q3	$41K	Hold	45,000	–	–	0.01%	148
2021 Q2	$41K	Buy	+45,000	New	+$32.7K	0.01%	174

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Equitec Proprietary Markets's SABSW Position: Q2 2023 in Review

Equitec Proprietary Markets sold out of SAB Biotherapeutics Warrant (SABSW) in Q2 2023, closing a stake of 45,000 shares — an estimated $1.62K sold.

Equitec Proprietary Markets first reported a position in SABSW in Q2 2021 and held it in 8 quarters. The position peaked at $81K in Q4 2021. 10 funds tracked by Wall St. Rank hold SABSW as of Q2 2023.

Equitec Proprietary Markets reported no remaining SAB Biotherapeutics Warrant position as of Q2 2023 after selling out during the quarter.
Equitec Proprietary Markets sold 45,000 SAB Biotherapeutics Warrant shares in Q2 2023, an estimated $1.62K.
Equitec Proprietary Markets first reported a position in SAB Biotherapeutics Warrant in Q2 2021 and held it in 8 quarters.
Equitec Proprietary Markets's SAB Biotherapeutics Warrant position peaked at $81K in Q4 2021.
10 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2023.

Based on Equitec Proprietary Markets's 13F filing for Q2 2023, filed 12 Jul 2023.